An analysis of 28 multicenter registries and nine randomized trials found that transcatheter aortic valve replacement (TAVR) studies tended to underestimate the incidence of permanent pacemaker implantations because they do not include patients who had permanent pacemakers before undergoing TAVR.

A pooled analysis of four cohort studies found that patients who did not have hypertension, obesity and diabetes by 45 to 55 years old had up to an 86 percent lower risk of developing heart failure during their lifetime.

After adjusting for age, researchers found that adults born in New Jersey from 1945 to 1954 had a significantly lower risk of stroke compared with those born in earlier or later time periods. The risk of ST-segment elevation MI (STEMI) was similar among the age groups.

Hefty growth is expected for the transcatheter aortic valve replacement and implantation (TAVR and TAVI) market, according to a new report that projects the market will be valued at $5.9 billion by 2022.

A new metallic heart stent from Berlin, Germany-based Biotronik was proved effective in new research presented at VEITHsymposium 2016, a cardiology conference in New York.

A retrospective database analysis found that the number of pulmonary arterial hypertension (PAH) hospitalizations per year decreased 58 percent from 2001 through 2012, although the mean hospital charge per admission increased 2.7-fold during that time period.

SentreHeart voluntarily recalled its FindrWIRZ guidewire system after discovering the device’s coating could separate from the packaging and potentially cause serious injuries.

Being extra thankful this Thanksgiving might give your heart health a boost, research suggests.